Pamalican Asset Management’s Humacyte HUMA Stock Holding History

Pamalican Asset Management’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-200,000	Closed	-$341K	–	2
2025 Q1	$341K	Buy	+200,000	New	+$751K	0.45%	8

Other funds holding HUMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CenterBook Partners Greenwich, Connecticut $2.04B AUM 35.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Pamalican Asset Management's HUMA Position: Q2 2025 in Review

Pamalican Asset Management sold out of Humacyte (HUMA) in Q2 2025, closing a stake of 200,000 shares — an estimated $341K sold.

Pamalican Asset Management first reported a position in HUMA in Q1 2025 and held it in 1 quarter. The position peaked at $341K in Q1 2025. 156 funds tracked by Wall St. Rank hold HUMA as of Q2 2025.

Pamalican Asset Management reported no remaining Humacyte position as of Q2 2025 after selling out during the quarter.
Pamalican Asset Management sold 200,000 Humacyte shares in Q2 2025, an estimated $341K.
Pamalican Asset Management first reported a position in Humacyte in Q1 2025 and held it in 1 quarter.
Pamalican Asset Management's Humacyte position peaked at $341K in Q1 2025.
156 funds tracked by Wall St. Rank held Humacyte as of Q2 2025.

Based on Pamalican Asset Management's 13F filing for Q2 2025.